Cost optimisation strategies across the CMC lifecycle without risking compliance Cost optimisation strategies across the CMC lifecycle without risking compliance Context The cost of developing pharmaceutical products is continuously rising, yet regulatory demands remain stringent. As such, the need for effective CMC cost optimisation outsourcing strategies is paramount. This manual aims to provide regulatory professionals with a thorough understanding of the considerations, regulations, and best practices for optimising costs in the Chemistry, Manufacturing, and Controls (CMC) lifecycle while ensuring compliance with FDA, EMA, and MHRA guidelines. Legal/Regulatory Basis Numerous regulations govern the CMC lifecycle across different regions, most notably: 21…

When to outsource CMC activities and when to keep them in house When to Outsource CMC Activities and When to Keep Them In-House Regulatory Affairs Context In the pharmaceutical and biotechnology industries, the management of Chemistry, Manufacturing, and Controls (CMC) is critical for ensuring compliance with regulatory requirements established by agencies such as the FDA, European Medicines Agency (EMA), and the Medicines and Healthcare products Regulatory Agency (MHRA). The decision to outsource CMC activities or to maintain these functions in-house is influenced by various factors, including regulatory expectations, cost considerations, and operational efficiencies. This article serves as a comprehensive guide…

Designing a hybrid CMC operating model with CDMOs and internal teams Designing a hybrid CMC operating model with CDMOs and internal teams Introduction In the context of pharmaceutical manufacturing, the integration of Contract Development and Manufacturing Organizations (CDMOs) into the Chemistry, Manufacturing, and Controls (CMC) lifecycle has become increasingly prevalent. This method not only enhances efficiency but also optimizes costs, ensuring that companies remain competitive in a fast-evolving market. Given the regulatory complexities that govern the pharmaceutical industry, it is imperative to design a hybrid CMC operating model that balances the engagement with CDMOs and internal capabilities. Regulatory Context The…

Total cost of ownership analysis for CMC outsourcing decisions Total Cost of Ownership Analysis for CMC Outsourcing Decisions The landscape of pharmaceutical and biotechnology industries is dynamic and increasingly competitive. Within this context, the importance of effective Contract Manufacturing Organization (CMO) or Contract Development and Manufacturing Organization (CDMO) partnerships has come to the forefront, especially in the realm of Chemistry, Manufacturing, and Controls (CMC) lifecycle management. This article is a comprehensive regulatory explainer manual aimed at providing Kharma and regulatory professionals with an in-depth understanding of the total cost of ownership (TCO) analysis relevant to CMC outsourcing decisions. Context CMC…

Negotiating quality and CMC terms in CDMO and CRO contracts Negotiating Quality and CMC Terms in CDMO and CRO Contracts Regulatory Affairs Context In the pharmaceutical and biotechnology sectors, the lifecycle management of Chemistry, Manufacturing, and Controls (CMC) is critical for ensuring that products meet regulatory requirements while being produced in a cost-effective manner. The significant outsourcing of CMC responsibilities to Contract Development and Manufacturing Organizations (CDMOs) and Contract Research Organizations (CROs) necessitates a deep understanding of the expectations from regulatory authorities such as the FDA, EMA, and MHRA. This article aims to provide a comprehensive overview of negotiating quality…

Using Portfolio Segmentation to Design Efficient CMC Outsourcing Strategies Using Portfolio Segmentation to Design Efficient CMC Outsourcing Strategies In the competitive landscape of pharmaceutical and biotechnology industries, effective management of the Chemistry, Manufacturing, and Controls (CMC) lifecycle is critical. Cost optimization through efficient outsourcing strategies has become increasingly important for Regulatory Affairs professionals. This article delves into using portfolio segmentation to design CMC outsourcing strategies, particularly focusing on the expectations of regulatory bodies such as the FDA, EMA, and MHRA. Regulatory Affairs Context Regulatory Affairs (RA) professionals play a crucial role in ensuring that drug products meet the requirements set…

KPIs to Track Cost, Quality and Speed in Outsourced CMC Work KPIs to Track Cost, Quality and Speed in Outsourced CMC Work The evolution of biopharmaceutical development necessitates a keen focus on CMC cost optimisation outsourcing, linking Regulatory Affairs (RA) with a robust CMC strategy. In today’s highly regulated environment, understanding how to optimize costs while ensuring compliance and quality is imperative. Context Effective outsourcing strategies in the CMC lifecycle can significantly influence a company’s ability to bring innovative products to market. The integration of external resources through Contract Development and Manufacturing Organizations (CDMOs) has become standard practice. Thus, Regulatory…

Case studies of CMC cost overruns and lessons for outsourcing models Case Studies of CMC Cost Overruns and Lessons for Outsourcing Models Regulatory Affairs Context In the dynamic landscape of biopharmaceutical development, Cost Management in the Chemistry, Manufacturing, and Controls (CMC) domain is pivotal. Regulatory Affairs (RA) professionals play a critical role in ensuring that all CMC activities align with regulatory expectations while maintaining cost efficiency. This regulatory explainer manual will delve into CMC cost optimization outsourcing strategies, underscored by real-world case studies showcasing cost overruns and lessons learned. Legal and Regulatory Basis The regulatory framework guiding CMC in the…

Building governance structures for multi CDMO CMC networks Building Governance Structures for Multi CDMO CMC Networks Context The CMC (Chemistry, Manufacturing, and Controls) lifecycle is critical in ensuring that pharmaceutical and biotech products meet regulatory requirements and quality standards. As organizations evolve, many are shifting towards outsourcing CMC functions to CDMO (Contract Development and Manufacturing Organizations) networks. This shift necessitates a robust governance structure to optimize costs, manage risks, and ensure compliance with regulatory expectations from agencies such as the FDA in the US, EMA in the EU, and MHRA in the UK. Legal/Regulatory Basis Understanding the legal and regulatory…

Risk management frameworks for outsourced CMC activities Risk management frameworks for outsourced CMC activities In the rapidly evolving pharmaceutical and biotech landscapes, companies increasingly outsource critical components of their Commercial Manufacturing and Control (CMC) lifecycle to Contract Development and Manufacturing Organizations (CDMOs). Integrating robust risk management frameworks becomes essential for ensuring compliance and optimizing costs. This article aims to guide regulatory professionals through the complexities of CMC cost optimisation outsourcing and the associated regulatory expectations focused on the US, UK, and EU markets. Regulatory Context Outsourcing CMC activities is not merely a business decision but a regulated endeavor that requires…